Rosen Law Firm is advising JSPR investors to consider their legal options following a class action lawsuit that highlights potential losses incurred during a key period for Jasper Therapeutics. This situation underscores the importance of vigilance among investors in the biotechnology sector, where market volatility can significantly impact financial outcomes.
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR), between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”). Jasper is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigat
Source: Original Press Release
